1. Stephen G. Marx Ph.D. Founder and CEO
Marx Biotechnology, Ltd.
Stephen G. Marx Ph.D.
Founder and CEO
All Contents are Proprietary Information of Marx Biotechnology LTD

2. www.marxbio.com All Contents are Proprietary Information of Marx Biotechnology LTD +972-52-869-3366

3. www.marxbio.com All Contents are Proprietary Information of Marx Biotechnology LTD +972-52-869-3366

4. 10 people per day
All Contents are Proprietary Information of Marx Biotechnology LTD

5. What is GVHD
50% bone marrow transplants patients will face a life- threatening complication called Graft Versus Host Disease (GVHD)
GVHD cannot be diagnosed until the patient develops observable symptoms.
Often, too late to save the patient’s life.
All Contents are Proprietary Information of Marx Biotechnology LTD

6. We are talking about Protein chip Unique set of Biomarkers
Our understanding of the GSK3beta molecule
All Contents are Proprietary Information of Marx Biotechnology LTD

7. Business Model USA Avalere Health
Changing the way physicians manage their patient
Creating a new industry standard
Europe
Costs
All Contents are Proprietary Information of Marx Biotechnology LTD

8. Disruptive technology
A market that is just waiting to grow
Annual allogeneic bone marrow transplantations market in the US and EU
600,000 test required annually equaling $350,000,000 market
Annual liver & intestine transplantations market in the US and EU
400,000 test required annually equaling $200,000,000 market
All Contents are Proprietary Information of Marx Biotechnology LTD

9. Doable Known technology Easy to use Easy to manufacture
All Contents are Proprietary Information of Marx Biotechnology LTD

10. No known barriers Current technology Other innovations
Marx Bio’s technology
Insurance coverage
All Contents are Proprietary Information of Marx Biotechnology LTD

11. Why the technology works
Based on known and established facts
Animal trials
Chief technical officer
Three components
Patents
FDA grant
All Contents are Proprietary Information of Marx Biotechnology LTD

12. Results: Mass Spectrometry
Comments
Sample 2 (Gsk3β+PKC)
Sample 1 (Gsk3β-PKC)
Already phosphorylated/auto-phosphorylated site, newly discovered site.
Thr324 1
Previously discovered site with unknown function.
Ser215 2
Ser219 3
Newly discovered site.
Thr309 4
Known inhibition site phosphorylated by several proteins, including PKC.
Ser9 5
Thr356 6
Known inhibition site phosphorylated by p38 MAPK.
Thr390 7
Thr392 8
Ser389 9
Nine phosphorylation sites were found on the Gsk3β incubated with PKC.
One of these sites was seen in the sample which contained Gsk3β alone, indicating that this site was previously phosphorylated or auto- phosphorylated.
The addtional 8 sites on Gsk3β are phosphorylated directly by PKC.
All Contents are Proprietary Information of Marx Biotechnology LTD

13. Results: T-cell Proliferation
Inhibitors group: Inhibiting 3 pathways significantly reduced cell proliferation in comparison to controls. Indicates that lower levels of Gsk3β phosphorylation is correlated with decreased cell proliferation.
PKC group: Activation of PKC (which phosphorylates Gsk3β) restores the cells to normal proliferation, despite other inhibitors. Indicates that Gsk3β phosphorylation can be correlated with an increase in proliferation.
PKC inhibited group: When all of the 4 major pathways are inhibited (and therefore Gsk3β is NOT phosphorylated), there is almost no cell proliferation. Indicates that Gsk3β regulates T-cell proliferation. * * **
***
p-value<0.01, statistical differences indicated by number of stars,
One-way ANOVA (Student-Newman-Keuls Method)
Experimental groups (in triplicates):
None – untreated cells
Inhibitors – treated with inhibitors against p38, Erk, and PI-3K pathways, with PKC unaffected
PKC activated – treated with inhibitors against p38, Erk, and PI-3K, and treated with PKC activator.
PKC inhibited – treated with inhibitors against p38, Erk, and PI-3K, and treated with PKC inhibitor
Statistics: p-value < 0.01, One-way ANOVA (Student-Newman-Keuls Method)
All Contents are Proprietary Information of Marx Biotechnology LTD

14. Proof of Concept: GVHD Mouse Model* **
***
**** * **
***
****
All Contents are Proprietary Information of Marx Biotechnology LTD

15. Why the technology works
Based on known and established facts
Animal trials
Chief technical officer
Three components
Patents
FDA grant
All Contents are Proprietary Information of Marx Biotechnology LTD

16. Patents The 1st IP The 2nd IP
A Kit for Monitoring, Detecting, and Staging GVHD
The Diagnostic Kit
The 2nd IP
Means and Methods for Diagnostics and Therapeutics of Diseases
The Core of the Technology
All Contents are Proprietary Information of Marx Biotechnology LTD

17. Why the technology works
Based on known and established facts
Animal trials
Chief technical officer
Three components
Patents
FDA grant
All Contents are Proprietary Information of Marx Biotechnology LTD

18. Simple , Doable, Manageable
How the Kit Works
Patient undergoes bone marrow transplant
Blood tests are taken routinely for the detection of GVHD (before symptoms develop)
The samples are processed and incubated on the protein chip.
Results are obtained within hours
Doctor receives real-time information of patient’s GVHD status
Improved health care and quality of life for patient
Simple , Doable, Manageable
All Contents are Proprietary Information of Marx Biotechnology LTD

19. Not just a single product
Technology based established facts
Other applications
Diagnostic and therapeutic
Personalized medicine
All Contents are Proprietary Information of Marx Biotechnology LTD

20. Experienced International Advisory Board
Diverse Team
Management Team
Experienced International Advisory Board
All Contents are Proprietary Information of Marx Biotechnology LTD

21. Milestones
Currently we are looking for $750K to cover the proof of concept study and to bring us to the next fundable milestones.
All Contents are Proprietary Information of Marx Biotechnology LTD

22. Marx Biotechnology, Ltd
Marx Biotechnology, Ltd. Contact Information
Marx Biotechnology Ltd Maavar Hamitla Street 3 Jerusalem Israel: 972 (0) America:
All Contents are Proprietary Information of Marx Biotechnology LTD